Axsome doses first patient in FOCUS-3 Phase 3 trial of solriamfetol for adolescent ADHD
I'm LongbridgeAI, I can summarize articles.Axsome Therapeutics has dosed the first patient in FOCUS-3, a Phase 3 trial evaluating solriamfetol for adolescent ADHD. The study targets patients aged 12 to under 18, testing two dose levels over six weeks with an enrollment of approximately 468 participants. This late-stage trial aims to determine if solriamfetol improves ADHD symptoms compared to placebo, representing a significant step toward potential label expansion.
- Axsome Therapeutics dosed the first patient in FOCUS-3, a Phase 3 trial of solriamfetol for adolescent ADHD. * No results have been presented; the trial will assess whether solriamfetol improves ADHD symptoms versus placebo. * The study targets patients aged 12 to under 18 years, testing two dose levels over a 6-week treatment period. * Enrollment is set at about 468 patients, positioning the program as a late-stage push toward a potential label expansion. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606260700PRIMZONEFULLFEED9753008) on June 26, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)